Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial. [electronic resource]
Producer: 20190903Description: 645-652 p. digitalISSN:- 1460-2385
- Adolescent
- Adult
- Age Factors
- Antidiuretic Hormone Receptor Antagonists -- therapeutic use
- Clinical Trials as Topic
- Disease Progression
- Female
- Gene Rearrangement
- Glomerular Filtration Rate -- drug effects
- Humans
- Hypertension -- physiopathology
- Kidney -- physiopathology
- Male
- Middle Aged
- Polycystic Kidney, Autosomal Dominant -- drug therapy
- Predictive Value of Tests
- Prospective Studies
- Research Design
- Risk Assessment -- methods
- Risk Factors
- Severity of Illness Index
- TRPP Cation Channels -- genetics
- Tolvaptan -- therapeutic use
- Young Adult
No physical items for this record
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.